Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company; Loxo Oncology, Inc.
• Collaborators: Eli Lilly and Company; Loxo Oncology, Inc.

Criteria

Inclusion Criteria:

• Advanced IDH mutant hematologic malignancy

• Patients must have received prior therapy

• Blasts at least 5% in bone marrow.

• Patients must have a qualifying IDH1 R132, IDH2 R140 or IDH2 R172 mutation

• Eastern Cooperative Oncology Group (ECOG) 0-2

• Adequate organ function

• Ability to swallow capsules or tablets

• Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation

• Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment.

Exclusion Criteria:

• Investigational agent or anticancer therapy within 2 weeks or 5 half-lives, whichever is shorter; or investigational monoclonal antibody within 4 weeks prior to planned start of LY3410738

• Major surgery within 4 weeks prior to planned start of LY3410738.

• Active, uncontrolled clinically significant systemic bacterial, viral, fungal or parasitic infection or an unexplained fever > 38.5ºC during screening or on the first day of study drug administration.

• Another concurrent malignancy requiring active therapy.

• Active central nervous system involvement

• Any unresolved toxicities from prior therapy greater than CTCAE v5.0 Grade 2 at the time of starting study treatment except for alopecia.

• History of hematopoietic stem cell transplant (HSCT) or CAR-T therapy within 60 days of the first dose of LY3410738

• Clinically significant cardiovascular disease

• Active hepatitis B virus (HBV)

• Active hepatitis C virus (HCV)

• Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug

• Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and/or P-gp inhibitor, with the exception of patients being treated with allowed antifungal inhibitors of CYP3A4

• Treatment with proton pump inhibitor (PPIs) within 7 days of starting LY3410738

• Any serious underlying medical or psychiatric condition (e.g. alcohol or drug abuse), dementia or altered mental status or any issue that would impair the ability of the patient to understand informed consent or that in the opinion of the investigator would contraindicate the patient's participation in the study or confound the results of the study

• Known human immunodeficiency virus (HIV), excluded due to potential drug-drug interactions between anti-retroviral medications and LY3410738

• Pregnancy, lactation or plan to breastfeeding during the study or within 90 days of the last dose of study intervention

• Known hypersensitivity to any of the components of LY3410738 or its formulation